-

Tubulis to Present at the 44th Annual J.P. Morgan Healthcare Conference

MUNICH--(BUSINESS WIRE)--Tubulis today announced that its CEO and Co-founder Dominik Schumacher will present a company overview and update at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.

The presentation will take place on Monday, January 12, 2026, at 3:00 pm PT in the Mission Bay Room (32nd Floor) at The Westin St. Francis.

About Tubulis

Tubulis generates uniquely matched antibody-drug conjugates with superior biophysical properties that have demonstrated durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models and first clinical proof-of-concept in platinum-resistant ovarian cancer. The two lead programs from our growing pipeline, TUB-040, targeting NaPi2b, and TUB-030, directed against 5T4, are being evaluated in the clinic in high-need solid tumor indications. We will solidify our leadership position by continuing to innovate on all aspects of ADC design leveraging our proprietary platform technologies. Our goal is to expand the therapeutic potential of this drug class for our pipeline, our partners and for patients. Visit www.tubulis.com or follow us on LinkedIn.

Contacts

For Tubulis
Dominik Schumacher, CEO & Co-founder
Phone: +49 (0) 175 800 5594
Email: contact@tubulis.com

Media Requests for Tubulis
Trophic Communications
Stephanie May, PhD
Phone: +49 (0) 171 185 56 82
Email: tubulis@trophic.eu

Industry:

Tubulis

Release Versions
English

Contacts

For Tubulis
Dominik Schumacher, CEO & Co-founder
Phone: +49 (0) 175 800 5594
Email: contact@tubulis.com

Media Requests for Tubulis
Trophic Communications
Stephanie May, PhD
Phone: +49 (0) 171 185 56 82
Email: tubulis@trophic.eu

Social Media Profiles
Tubulis on LinkedIn
Tubulis on Twitter
More News From Tubulis

Tubulis to Present Phase I/IIa Trial Data for ADC Candidate TUB-040 in Platinum-resistant Ovarian Cancer in Rapid Oral Presentation at ASCO 2026

MUNICH--(BUSINESS WIRE)--Tubulis today announced that an abstract covering current clinical trial data from its ongoing Phase I/IIa NAPISTAR 1-01 trial (NCT06303505) has been accepted for a rapid oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Meeting, being held May 29 - June 2, 2026, in Chicago. The presentation by Prof. Dr. Toon Van Gorp, clinical investigator of the study, will provide an update of maturing data from the ongoing dose escalation part of the ova...

Tubulis Adds Steve Kelsey as Independent Director to its Advisory Board

MUNICH--(BUSINESS WIRE)--Tubulis today announced the appointment of Steve Kelsey, MD, as independent director to its Advisory Board. Dr. Kelsey, currently President, Research and Development at Revolution Medicines, brings more than two decades of global biotechnology experience spanning small molecules, antibodies and antibody drug conjugates (ADCs), with a strong track record of translating innovative science into approved and transformative oncology therapies. As independent director, he wil...

Tubulis Unveils Alco5 Conjugation Platform’s Ability to Expand ADC Payload Scope in Nature Communications

MUNICH--(BUSINESS WIRE)--Tubulis today announced the publication of preclinical proof-of-concept data for its novel Alco5 conjugation platform in Nature Communications. The paper describes the company’s novel antibody-drug conjugate (ADC) technology and highlights its ability to link antibodies with an expanded set of previously inaccessible hydroxy-containing payloads. This new chemical concept has the potential to open new therapeutic avenues in cancer treatment and counteract resistance by e...
Back to Newsroom